The research developed throughout my career on the one side contributed to advance the knowledge of the mechanisms underlying the transport of molecules (lipids, proteins and supramolecular complexes) across the blood-brain barrier (BBB) and the connections with cerebral amyloidosis. More precisely, I investigated the molecular mechanisms underlying the dynamics of aggregation, disaggregation and clearance of amyloid-beta peptide, which accumulates in high amounts within the brain of Alzheimer’s and Cerebral Amyloid Angiopathy patients and plays a central role in the pathogenesis of these diseases. The combination of the accumulated expertise on these issues allowed myself to devise new strategies for the therapy of Alzheimer’s disease, based on nanomedicine tools, by designing nanoparticles (liposomes) able to cross the BBB and to target amyloid-beta peptide, destabilizing its aggregates and preventing their accumulation in the brain. A proof-of-principle has been obtained in animal models of Alzheimer disease. The I.P. related to these liposomes has been protected by two families of Patents and a Spin-off company has been established (AmypoPharma S.r.l., Milano), in which I am currently CSO. Within the objectives of the company I have develop expertises in studying the effect of nanoparticles on different amyloidogenic proteins and in controlling their aggregation in vitro. Related to the above said topics I have coordinated an EU project, awarded by a JPND funding (Development of a Novel Multicellular In Vitro Model of Alzheimer’s disease like Blood-Brain Barrier, NAB3), aiming to develop advanced experimental cellular models of the BBB, to reproduce features present in neurodegenerative diseases. Currently, my research focus is on the design of drug delivery systems for brain diseases treatment (in particular central amyloidosis and glioblastoma). I have published 64 scientific papers on top international peer-reviewed journals; my h-index is 25 with 1921 citations (Scopus). In 2013, I was awarded of “63rd Lindau Nobel Laureate Meeting – Chemistry”. I am member of the Editorial Board of different Journals (Journal of Nanoscience, Nanomedicine & Nanobiology; Nanobiomedicine Journal; Journal of Nanotechnology and Nanomedicine). I had three career intermissions between 2009 and 2016 due to maternity leave.